Adamas Pharmaceuticals Inc said on Tuesday its drug to treat walking impairment in patients with Multiple Sclerosis did not show the clinical benefit the drugmaker was hoping for in a late-stage trial.Reuters Health Information (Source: Medscape Allergy Headlines)

Read full article on

Powered by Preisvergleich


Follow Us on Twitter

Follow Us On Twitter - Image